Tender Results of Nhs England

NHS National Framework Agreement for the supply of Adalimumab Injection 1 April 2023-Project Title: NHS National Framework Agreement for the supply of Adalimumab Injection 1 April 2023 Offer reference number: CM/PHR/22/5660 CM/PHR/22/5660/01 - NHS Framework Agreement for the supply of Adalimumab Injection to South of England. Period of framework: 1 April 2023 to 31 August 2024 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months CM/PHR/22/5660/02 - NHS Framework Agreement for the supply of Adalimumab...

PRJ1146 Prison Healthcare Services-This award notice concerns the procurement to deliver Integrated Prison Healthcare Services, acting as the Prime Provider in the following establishments in London: Lot 1 - HMP Belmarsh & HMP Thameside

NHS Framework Agreement-Branded Medicines - National Proprietary Pharmaceuticals-NHS Framework Agreement for Branded Medicines - National Proprietary Pharmaceuticals Offer reference number: CM/PHR/22/5675 CM/PHR/22/5675/01 - NHS Framework Agreement for Branded Medicines - National Category Tender Lot 1. Period of framework: 1 May 2023 to 30 April 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months CM/PHR/22/5675/02 - NHS Framework Agreement for Branded Medicines - National Tender Lot 2. Per...

NHS Branded Medicines Tranche Framework for London and South of England-NHS Branded Medicines Tranche Framework for London and South of England - 1 September 2024 Offer reference number: CM/PHR/22/5689 CM/PHR/22/5689/01 - NHS Framework for Branded Medicines - London & South of England Tranche A. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5689/02 - NHS Framework for Branded Medicines - London & South of E...

NHS National Generic Pharmaceuticals Wave 14c (CF Award - Part 2)-Invitation to offer for NHS National Generic Pharmaceuticals - Wave 14c Offer reference number: CM/PHG/22/5672 Period of framework agreement: The total maximum duration of the framework agreement to be no more than 36 months with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 48 months. Potential periods of call-offs under the framework agreement: Orals (plus non-parenteral) Products: All Regions (CESW/LSNE/NWLN):01/06/2024 to 3...

NHS National Generic Pharmaceuticals Wave 14c (CF Award - Part 1)-Invitation to offer for NHS National Generic Pharmaceuticals - Wave 14c Offer reference number: CM/PHG/22/5672 Period of framework agreement: The total maximum duration of the framework agreement to be no more than 36 months with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 48 months. Potential periods of call-offs under the framework agreement: Orals (plus non-parenteral) Products: All Regions (CESW/LSNE/NWLN):01/06/2024 to 3...

NHS National Generic Pharmaceuticals Wave 14a-Invitation to offer for NHS National Generic Pharmaceuticals Wave 14a
Offer reference number: CM/PHG/22/5657/03
Period of framework agreement: The total maximum duration of the framework agreement to be no more than 24 months with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 48 months.
Potential periods of call-offs under the framework agreement:
Housekeeping Products (Hospital Only): CESW 01/02...

National Framework Agreement for Adalimumab Injection 1 April 2023-Lot 1 - CM/PHR/22/5660/01 - NHS Framework Agreement for the supply of Adalimumab Injection to South of England. Period of framework: 1 April 2023 to 31 August 2024 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months

NHS North of England Branded Medicines Tranche A & Annual Tranche-Lot 1 - CM/PHR/20/5606/01 - NHS Framework for North of England Branded Medicines - Tranche A. Period of framework: 1 March 2023 to 28 February 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months

NHS National Generic Pharmaceuticals Wave 14a-Invitation to offer for NHS National Generic Pharmaceuticals Wave 14a Offer reference number: CM/PHG/22/5657 Period of framework agreement: The total maximum duration of the framework agreement to be no more than 24 months with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 48 months. Potential periods of call-offs under the framework agreement: Hospital Only Products: DLN & DNW 01/02/2023 - 31/01/2025 (24 Months)